ENGLEWOOD, Colo., Dec. 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSEAmerican:AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.
Read more at prnewswire.comAmpio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/A%20photo%20of%20a%20Sandisk%20Solid%20State%20Drive%20by%20Top%20Popular%20Vector%20by%20Shutterstock.jpg)
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
